好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Goals and Design of a Dedicated Tertiary Care Centre NMOSD/MOGAD Clinic
Autoimmune Neurology
P2 - Poster Session 2 (2:45 PM-3:45 PM)
019
To review and share the process and design of patient clinic dedicated to the care of patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Antibody-Associated Disease (MOGAD).

Patients with NMOSD and MOGAD have time-sensitive and specific needs that may not be adequately addressed in a large, undifferentiated demyelinating disease clinic. This includes rapid assessment in suspected NMSOD relapses, arranging relapse therapy such as plasmapheresis, and enrolment in trials of putative therapies.

Providers with the greatest expertise and complement of NMOSD and MOGAD patients, in consultation with providers in other provincial centers, came to a consensus about patient criteria (suspected, probable, and confirmed MOGAD and NMOSD), triage acuity, visit frequency, transition from inpatient to clinic processes, Neuro-ophthalmology participation, trainee involvement, and nursing support to oversee treatment pathways.
The University of Calgary NMOSD/MOGAD clinic was developed to run once monthly staffed by three dedicated staff. Eligible patients are those with confirmed or probable seropositive or seronegative NMOSD, or MOGAD, including those with ADEM, cortical encephalitis, recurrent optic neuritis and/or myelitis AFTER appropriate investigations. Patients with suspected or newly confirmed NMOSD/MOGAD receiving acute relapse treatment requiring medication tapering and maintenance therapy, or those referred from Ophthalmology or Neurology actively relapsing and needing acute treatment guidance, will be deemed urgent. Patients with probable or newly confirmed MOGAD/NMOSD and a recent suspicious event successfully treated who may have already started a maintenance therapy, or patients with probable NMOSD in remission, but not on maintenance therapy will be deemed semi-urgent.

We believe focused NMOSD/MOGAD care directed through a dedicated clinic with appropriate staffing and processes will result in better outcomes and patient satisfaction. We will review clinic outcomes and issues at 6 months intervals after initiation.
Authors/Disclosures
Jodie Burton, MD, FAAN
PRESENTER 		Dr. Burton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Burton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Burton has received personal compensation in the range of $0-$499 for serving as a Consultant for Horizon. The institution of Dr. Burton has received research support from Roy and Joan Allen Professorship for Sight. Dr. Burton has a non-compensated relationship as a Advisor with CADTH that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Alexion that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Horizon that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a 好色先生al Chair with EMD Serono that is relevant to AAN interests or activities.
Katayoun Alikhani, MD (South Health Campus) Dr. Alikhani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apotex, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Roche, Sanofi Genzyme.
Tyson Brust, MD (University of Calgary) Dr. Brust has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Brust has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Brust has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Brust has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono.
Fiona E. Costello, MD (Fiona Costello Professional Corporation) Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Accure Therapeutics. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for the Sumaira Foundation.
Colleen Harris Colleen Harris has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Pharmceuticals. Colleen Harris has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hoffman LaRoche Canada. Colleen Harris has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono.
Sarah A. Morrow, MD, MSC, FRCPC, FAAN Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono/Merck. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Morrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SanofiGenzyme. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Morrow has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Morrow has received research support from Celgene. The institution of Dr. Morrow has received research support from SanofiGenzyme. The institution of Dr. Morrow has received research support from Novartis.